APG-3526 / Ascentage Pharma - LARVOL DELTA

"Ascentage Pharma presents APG-3526 as a novel and highly potent MCL-1 inhibitor, showing antitumor activity in xenograft mice models." (@Cortellis)

Preclinical • Oncology

[VIRTUAL] Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor (AACR-II 2020) - "In conclusion, we have developed a novel and highly potent MCL-1 inhibitor, APG-3526, which displays clinically relevant pharmacokinetic properties and elicits potent antiproliferative and antitumor activities via disrupting MCL-1 complex and triggering caspase activation, especially in MCL-1 driven MM models. These results support APG-3526 as a promising MCL-1inhibitor for further clinical development."

IO Biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Breast Cancer • Cervical Cancer • Chronic Lymphocytic Leukemia • Gynecologic Cancers • Leukemia • Melanoma • Multiple Myeloma • Oncology • Ovarian Cancer • BCL2 • CASP3